| London Stock Exchange: VAL
ValiRx Plc is a biopharmaceutical company that is engaged in developing novel technologies and products in oncology therapeutics and diagnostics. The company's product focus is on the epigenomic analysis and treatment of cancer as well as the technologies can be also applied in other fields, such as neurology and inflammatory diseases. ValiRx operates through three divisions, ValiPharma, a UK based epigenetic drug discovery and development business, ValiBio, a Belgium-based oncology diagnostics and biomarker business and ValiMedix, a UK based trading business. The company was founded on June 1, 2006 and is headquartered in London, the United Kingdom.